Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06391242

Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

BCCA - Vancouver, Vancouver, British Columbia, Canada

Loading trial locations.

About this study

This is a multi-centre, phase III randomized controlled trial comparing SBRT to conventional palliative EBRT in patients with solid tumours and a dominant painful non-spine bone metastasis as defined by a worst pain score of 2 or greater. 230 participants will be enrolled to the study. Participants will have radiation for 5 treatments (conventional palliative EBRT 20Gy/5; SBRT 30Gy/5 or 35Gy/5) and then will be followed for pain response and radiological progression at 3 and 6 months post treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologic confirmation of solid tumour.
  • Patient with a dominant painful non-spine bone metastasis and a worst minimum pain score of 2 using the BPI attributed to that dominant site
  • Expected overall survival of greater than 6 months as determined by the treating physician
  • Suitable for protocol defined SBRT and CRT.
  • Stable pain with no immediate plan to alter analgesic regimen.
  • ECOG performance status of 0-2.
  • Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate

Exclusion criteria

  • Metastases of the hands, feet, cranium or spine (including sacrum) as the dominant/index pain site.
  • Bone metastasis arising from a small cell or germ cell.
  • Radionuclide therapy within 30 days of randomization.
  • Patient treated with prior palliative RT to the dominant painful bone metastasis site (prior radiation exposure is permitted if prior to development of the dominant metastasis and would not influence the applicability of either treatment arm of the current study).
  • Received systemic chemotherapy within 1 week of the protocol RT, or who are expected/planned to receive chemotherapy within one week of completing protocol RT.
  • Participants with an unstable pathologic fracture at the dominant painful bone metastasis, or for whom surgical fixation would be the preferred intervention if possible.
  • Pregnant or lactating individuals.

Treatment and study plan

Standard Conventional Radiotherapy

Radiation

20Gy in 5 fractions

stereotactic body radiotherapy

Radiation

30 or 35Gy in 5 fractions

Primary outcomes

  1. Complete pain response utilizing the Cochran-Mantel-Hanzeal test

    Time frame: 27 months

Secondary outcomes

  1. Pain response pattern at 3 months: partial, stable or progressive pain

    Time frame: 27 months

  2. Early (1 month post RT) and late (6 months post RT) CPR and response patterns (partial, stable, and progressive pain);

    Time frame: 27 months

  3. Re-irradiation rate within the 6-month follow-up period

    Time frame: 27 months

  4. Incidence of fracture at the radiation target site

    Time frame: 27 months

  5. Incidence of treatment-related AE rates >/- grade 2 utilizing CTCAE v5

    Time frame: 27 months

  6. Imaging-based local control rates at 3 and 6 months post-treatment

    Time frame: 27 months

  7. Patient reported outcomes utilizing EORTC QLQ-C30

    Time frame: 27 months

  8. Patient reported outcomes utilizing EORTC QLQ-BM22

    Time frame: 27 months

Study contacts

Contact information is provided by the study sponsor or research team.

Wendy Parulekar

CONTACT

[email protected]

613-533-6430

Sponsors and collaborators

Lead sponsor

Canadian Cancer Trials Group

Network

Registry information

Official study title

A Randomized Phase III Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Participants With Painful Non-Spine Bone Metastases

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 30, 2024
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.